Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer

Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer

Abstract Background FOLFOXIRI plus bevacizumab is used as a first-line therapy for patients with unresectable or metastatic colorectal cancer. However, there are no clear recommendations for second-line therapy after FOLFOXIRI plus bevacizumab combination. Here, we describe our planning for the EFFO...

Full description

Bibliographic Details
Main Authors: Hironaga Satake, Koji Ando, Eiji Oki, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Akihito Tsuji, Masaki Mori
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Cancer
Subjects:
Colorectal cancer
Aflibercept
FOLFIRI
Second line
FOLFOXIRI
Bevacizumab
Online Access:http://link.springer.com/article/10.1186/s12885-020-07576-9

Internet

http://link.springer.com/article/10.1186/s12885-020-07576-9

Similar Items